optometryadvisor1 日
Real-World Data on Novel Ocular Surface Disease Drugs Are In
Perfluorohexyloctane and lotilaner ophthalmic solution, 2 ocular surface disease drugs, have changed the DED and DB treatment paradigms.
Tarsus Pharmaceuticals: Strong Market Penetration and Promising Expansion into Ocular Rosacea
Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...
Orange County Business Journal5 日
Bobak Azamian: Clearing Crusty Eyelids for Millions of Americans
Tarsus Pharmaceuticals, which has more than 100 of its 331 employees in Orange County, has plans to double its office space ...
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular ...
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no ...